Live Wire Reporter

Onychomycosis Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects, and Future Onychomycosis Pipeline Landscape

Onychomycosis Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects, and Future Onychomycosis Pipeline Landscape

November 25
19:21 2022
Onychomycosis Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects, and Future Onychomycosis Pipeline Landscape

DelveInsight’s, “Onychomycosis Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Onychomycosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Recent Developmental Activities in the Onychomycosis Pipeline Insight Report

  • MOB-015 is an internally developed topical formulation of terbinafine based on Moberg Pharma’s experience from previously having developed and commercialized a leading OTC product for onychomycosis. MOB-015 has recently been evaluated over 52 weeks in two randomized, multicenter, controlled Phase III studies, including in total more than 800 patients in North America and Europe. The primary endpoint was met in both studies, the proportion of patients achieving complete cure of their target nail.Moberg Pharma AB (publ) have submitted its marketing authorization application for MOB-015 (nail fungus treatment). The company has submitted the application in Europe through the decentralized procedure, and market approval is expected in 2023.
  • Blueberry is developing a new topical antifungal spray formulation of terbinafine (BB2603‑om) for the treatment of onychomycosis using our nanodelivery platform technology. The aim is to apply the spray directly to the nail, and through enhanced delivery of the active substance through the nail, to match the cure rates of the more effective oral formulations in a topical medicine, without the associated safety concerns.

 

Key takeaways from the Onychomycosis Pipeline Report

  • DelveInsight’s analysis presents the Onychomycosis Pipeline with 15+ active players in the domain investigating 15+ pipeline therapies.
  • The leading Onychomycosis Companies are working such as Moberg Pharma, Blueberry Therapeutics, DermBiont, Sanotize Research and Development, Meiji Seika Pharma, NovaBiotics, Polichem, Hallux, Hexima, Turn Therapeutics, 9305-9954 Quebec, Mycovia Pharmaceuticals, CSA BioTech, Kaken Pharmaceutical, Turn Therapeutics, and others.
  • Promising Onychomycosis Pipeline therapies such as MOB‐015, BB2603, TDT067 and Lamisil, Albaconazole 100mg, Itraconazole 100mg capsules, BB2603-1, BB2603-3, BB2603-10, SKX-16, P-3058 10%, amorolfine 5%, and others.
  • The Onychomycosis Companies and academics are working to assess challenges and seek opportunities that could influence Onychomycosis R&D. The therapies under development are focused on novel approaches to treat/improve Onychomycosis.

 

Request for Sample to know which pharma company is expected to be at the forefront in the coming years @ Onychomycosis Pipeline Outlook Report

 

Onychomycosis Overview

Onychomycosis is fungal infection of the nail plate, nail bed, or both. The nails typically are deformed and discolored white or yellow. Diagnosis is by appearance, wet mount, culture, polymerase chain reaction, or a combination. Treatment, when indicated, is with oral terbinafine or itraconazole. Onychomycosis is suspected by appearance in patients who also have tinea pedis; predictive clinical features include involvement of the 3rd or 5th toenail, involvement of the 1st and 5th toenails on the same foot, and unilateral nail deformity. Subclinical onychomycosis should be considered in patients with recurrent tinea pedis.

 

Onychomycosis Pipeline Insight Report

In the Onychomycosis pipeline insight report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Onychomycosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Onychomycosis Emerging Drugs

  • MOB‐015: Moberg Pharma
  • BB2603: Blueberry Therapeutics

 

Request for Sample to know more @ Onychomycosis Pipeline Analysis, Key Companies, and Futuristic Trends

 

Onychomycosis Pipeline Therapeutics

The Onychomycosis Pipeline report proffers an integral view of the Onychomycosis emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

 

Onychomycosis Pipeline Assessment

There are approx. 15+ key companies which are developing the therapies for Onychomycosis. The companies which have their Onychomycosis drug candidates in the most advanced stage, i.e. Preregistration include, Moberg Pharma.

 

Scope of the Onychomycosis Pipeline Insight Report

  • Coverage- Global
  • Onychomycosis Companies- Moberg Pharma, Blueberry Therapeutics, DermBiont, Sanotize Research and Development, Meiji Seika Pharma, NovaBiotics, Polichem, Hallux, Hexima, Turn Therapeutics, 9305-9954 Quebec, Mycovia Pharmaceuticals, CSA BioTech, Kaken Pharmaceutical, Turn Therapeutics, and others.
  • Onychomycosis Pipeline therapies- MOB‐015, BB2603, TDT067 and Lamisil, Albaconazole 100mg, Itraconazole 100mg capsules, BB2603-1, BB2603-3, BB2603-10, SKX-16, P-3058 10%, amorolfine 5%, and others

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Onychomycosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Preregistration)
  7. MOB‐015: Moberg Pharma
  8. Drug profiles in the detailed report…..
  9. Late Stage Products (Phase III)
  10. Drug Name: Company Name
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. BB2603: Blueberry Therapeutics
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. Drug Name: Company Name
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. GX-03: Turn Therapeutics
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Onychomycosis Key Companies
  23. Onychomycosis Key Products
  24. Onychomycosis- Unmet Needs
  25. Onychomycosis- Market Drivers and Barriers
  26. Onychomycosis- Future Perspectives and Conclusion
  27. Onychomycosis Analyst Views
  28. Onychomycosis Key Companies
  29. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Onychomycosis drugs?
  • How many Onychomycosis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Onychomycosis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Onychomycosis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Onychomycosis and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Discover more about the scope of the report @ Onychomycosis Clinical Trials Analysis Report

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Author

admin

admin